| 1. Bone marrow involvement by primary oxalosis |
Page:192—192 |
| 2. COVID-19 in a patient with chronic myelomonocytic leukemia: a twisting tale |
Page:278—281 |
| 3. Outcomes of patients with essential thrombocythemia and unnoticed thrombocytosis prior to diagnosis |
Page:281—282 |
| 4. Pulmonary embolism rate in patients infected with SARS-CoV-2 |
Page:275—278 |
| 5. The detection of Howell-Jolly body-like inclusions in a case of coronavirus disease-2019 (COVID-19) |
Page:191—191 |
| 6. Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey |
Page:206—212 |
| 7. Prognostic value of TNF-α-308 and IFN-γ-874 single nucleotide polymorphisms and their plasma levels in patients with aplastic anemia |
Page:193—199 |
| 8. Mining of mortality-related findings in rare bleeding disorders:a retrospective study from two centers |
Page:213—216 |
| 9. Radiotherapy for non-gastric intestinal versus gastric MALT lymphoma: a comparison of treatment outcomes |
Page:200—205 |
| 10. Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era |
Page:217—224 |
| 11. Changing the frequency and spectra of chromosomal aberrations in Korean patients with acute leukemia in a tertiary care hospital |
Page:225—245 |
| 12. First report of the unique expression of RECAF (receptor for alfa feto-protein) in adult B-NHL/CLL patients |
Page:253—261 |
| 13. Safety and effectiveness of Rixubis in patients with hemophilia B:a real-world, prospective, postmarketing surveillance study in South Korea |
Page:246—252 |
| 14. Long-term treatment outcomes of children and adolescents with lymphoblastic lymphoma treated with various regimens:a single-center analysis |
Page:262—274 |
| 15. Classification of acute myeloid leukemia |
Page:S1—S4 |
| 16. New agents in acute myeloid leukemia (AML) |
Page:S14—S18 |
| 17. AL amyloidosis: advances in diagnosis and management |
Page:S54—S57 |
| 18. Extranodal NK/T cell lymphoma |
Page:S63—S71 |
| 19. Recent advances in chronic lymphocytic leukemia therapy |
Page:S72—S82 |
| 20. Treatments for children and adolescents with AML |
Page:S5—S13 |
| 21. Recent advances in the management of primary central nervous system lymphoma |
Page:S58—S62 |
| 22. Treatment of relapsed and refractory multiple myeloma |
Page:S43—S53 |
| 23. Optimal therapy for adolescents and young adults with acute lymphoblastic leukemia-current perspectives |
Page:S27—S31 |
| 24. Frontline therapy for newly diagnosed patients with multiple myeloma |
Page:S37—S42 |
| 25. Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation |
Page:S19—S26 |
| 26. Current treatment strategies for Philadelphia chromosome-positive adult acute lymphoblastic leukemia |
Page:S32—S36 |
| 27. Chronicles of blood morphology associated with steroid use |
Page:128—128 |
| 28. An interesting story of a clone |
Page:115—117 |
| 29. Response of multifocal acquired demyelinating sensorimotor neuropathy associated with atypical chronic lymphocytic leukemia to rituximab therapy |
Page:117—120 |
| 30. Adult T-cell leukemia/lymphoma and Glucose-6-phosphate dehydrogenase deficiency rapidly diagnosed through blood smear examination |
Page:76—76 |
| 31. Large granular lymphocytes (LGL) in primary Sjögren syndrome (pSS): immunophenotype and review on the pathological role of T cells in pSS |
Page:120—123 |
| 32. Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab |
Page:75—75 |
| 33. Chronic phase of chronic myeloid leukemia presenting with myeloid sarcoma in an adolescent |
Page:112—115 |
| 34. Atypical presentation of hairy cell leukemia: a report and comprehensive review |
Page:123—127 |
| 35. Coronavirus disease-19 and its hematological manifestations |
Page:71—74 |
| 36. Impact of using genotyping to predict SERF negative phenotype in Thai blood donor populations |
Page:107—111 |
| 37. Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study |
Page:85—90 |
| 38. Natural soluble human leukocyte antigen class I in donor serum neutralizes donor-specific HLA alloantibodies in recipient serum |
Page:91—98 |
| 39. Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients |
Page:77—84 |
| 40. Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma |
Page:99—106 |
| 41. Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how? |
Page:67—68 |
| 42. Response to the letter by Langabeer on “Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria†|
Page:68—68 |
| 43. Helicobacter pylori testing in a population of Korean patients with pernicious anemia |
Page:69—69 |
| 44. Clinical significance of myeloproliferative neoplasms with JAK2V617F mutations and major BCR-ABL1 translocations: a literature review with case presentation |
Page:62—65 |
| 45. Daratumumab in dialysis-dependent multiple myeloma |
Page:65—67 |
| 46. Bibliometric analysis of studies about acute myeloid leukemia conducted globally from 1999 to 2018 |
Page:1—9 |
| 47. Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience |
Page:57—61 |
| 48. Characteristics of DNMT3A mutations in acute myeloid leukemia |
Page:17—26 |
| 49. A general view of CD33⺠leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy |
Page:10—16 |
| 50. Human platelet lysate efficiency, stability, and optimal heparin concentration required in culture of mammalian cells |
Page:35—43 |
| 51. Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome |
Page:27—34 |
| 52. Thromboprophylaxis after bariatric surgery |
Page:44—48 |
| 53. HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases |
Page:49—56 |
| 54. Successful response with romidepsin in relapsed peripheral T-cell lymphoma, not otherwise specified with leukemic progression |
Page:175—177 |
| 55. Identifying the link between multiple myeloma and neurofibromatosis type I |
Page:187—189 |
| 56. An illustrative case of B-cell prolymphocytic leukemia |
Page:181—184 |
| 57. Nuances in the management of acquired hemophilia A in an elderly patient with large granular lymphocytic leukemia |
Page:180—181 |
| 58. Acute myeloid leukemia with myelodysplasia-related changes and basophilic differentiation |
Page:130—130 |
| 59. Peripheral blood histoplasmosis in an immunocompetent child with disseminated disease |
Page:129—129 |
| 60. Hb-M Hyde Park: a rare cause of cyanosis arising from a de novo mutation |
Page:177—180 |
| 61. Rapid resolution of bone marrow necrosis mimicking relapse of pediatric acute lymphoblastic leukemia |
Page:184—187 |
| 62. Utility of screening tools to differentiate beta thalassemia trait and iron-deficiency anemia - do they serve a purpose in blood donors? |
Page:169—174 |
| 63. Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression |
Page:131—138 |
| 64. Rare bleeding disorders: spectrum of disease and clinical manifestations in the Pakistani population |
Page:146—150 |
| 65. KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute |
Page:159—168 |
| 66. Drug use evaluation of opioid analgesics in pain management among patients with hematopoietic stem cell transplantation |
Page:151—158 |
| 67. Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study |
Page:139—145 |
